vs
Side-by-side financial comparison of Boston Scientific (BSX) and Philip Morris International (PM). Click either name above to swap in a different company.
Philip Morris International is the larger business by last-quarter revenue ($10.1B vs $5.2B, roughly 2.0× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 24.0%, a 1.7% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs 9.1%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs 3.5%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Philip Morris International Inc. (PMI) is a tobacco company, with products sold in over 180 countries. Marlboro is PMI’s most recognized brand, but in the last quarter of 2023, Iqos generated the greatest revenue. Philip Morris International is often referred to as one of the companies comprising Big Tobacco. The company ranked No. 121 in the 2025 Fortune 500 list of the largest US corporations by total revenue.
BSX vs PM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $10.1B |
| Net Profit | $1.3B | $2.4B |
| Gross Margin | 69.5% | 68.1% |
| Operating Margin | — | 38.4% |
| Net Margin | 25.7% | 24.0% |
| Revenue YoY | 11.6% | 9.1% |
| Net Profit YoY | — | -9.0% |
| EPS (diluted) | $0.90 | $1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | $10.1B | ||
| Q4 25 | $5.3B | $10.4B | ||
| Q3 25 | $5.1B | $10.8B | ||
| Q2 25 | $5.1B | $10.1B | ||
| Q1 25 | $4.7B | $9.3B | ||
| Q4 24 | $4.6B | $9.7B | ||
| Q3 24 | $4.2B | $9.9B | ||
| Q2 24 | $4.1B | $9.5B |
| Q1 26 | $1.3B | $2.4B | ||
| Q4 25 | $670.0M | $2.1B | ||
| Q3 25 | $755.0M | $3.5B | ||
| Q2 25 | $795.0M | $3.0B | ||
| Q1 25 | $672.0M | $2.7B | ||
| Q4 24 | $563.0M | $-579.0M | ||
| Q3 24 | $468.0M | $3.1B | ||
| Q2 24 | $322.0M | $2.4B |
| Q1 26 | 69.5% | 68.1% | ||
| Q4 25 | 69.6% | 65.6% | ||
| Q3 25 | 69.9% | 67.8% | ||
| Q2 25 | 67.7% | 67.7% | ||
| Q1 25 | 68.8% | 67.3% | ||
| Q4 24 | 67.8% | 64.7% | ||
| Q3 24 | 68.8% | 66.0% | ||
| Q2 24 | 69.2% | 64.7% |
| Q1 26 | — | 38.4% | ||
| Q4 25 | 15.6% | 32.6% | ||
| Q3 25 | 20.7% | 39.3% | ||
| Q2 25 | 16.2% | 36.6% | ||
| Q1 25 | 19.8% | 38.1% | ||
| Q4 24 | 14.8% | 33.6% | ||
| Q3 24 | 17.4% | 36.9% | ||
| Q2 24 | 12.6% | 36.4% |
| Q1 26 | 25.7% | 24.0% | ||
| Q4 25 | 12.7% | 20.7% | ||
| Q3 25 | 14.9% | 32.1% | ||
| Q2 25 | 15.7% | 30.0% | ||
| Q1 25 | 14.4% | 28.9% | ||
| Q4 24 | 12.3% | -6.0% | ||
| Q3 24 | 11.1% | 31.1% | ||
| Q2 24 | 7.8% | 25.4% |
| Q1 26 | $0.90 | $1.56 | ||
| Q4 25 | $0.45 | $1.36 | ||
| Q3 25 | $0.51 | $2.23 | ||
| Q2 25 | $0.53 | $1.95 | ||
| Q1 25 | $0.45 | $1.72 | ||
| Q4 24 | $0.38 | $-0.37 | ||
| Q3 24 | $0.32 | $1.97 | ||
| Q2 24 | $0.22 | $1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $5.5B |
| Total DebtLower is stronger | — | $49.5B |
| Stockholders' EquityBook value | — | — |
| Total Assets | — | $68.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.5B | ||
| Q4 25 | $2.0B | $4.9B | ||
| Q3 25 | $1.3B | $4.0B | ||
| Q2 25 | $534.0M | $4.1B | ||
| Q1 25 | $725.0M | $4.4B | ||
| Q4 24 | $414.0M | $4.2B | ||
| Q3 24 | $2.5B | $4.3B | ||
| Q2 24 | $2.9B | $4.8B |
| Q1 26 | — | $49.5B | ||
| Q4 25 | $11.1B | $45.1B | ||
| Q3 25 | $11.1B | $41.9B | ||
| Q2 25 | $11.1B | $42.4B | ||
| Q1 25 | $10.5B | $38.8B | ||
| Q4 24 | $9.0B | $42.2B | ||
| Q3 24 | $9.2B | $44.2B | ||
| Q2 24 | $9.0B | $44.6B |
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $-10.0B | ||
| Q3 25 | $23.4B | $-10.9B | ||
| Q2 25 | $22.4B | $-12.0B | ||
| Q1 25 | $22.2B | $-10.9B | ||
| Q4 24 | $21.8B | $-11.8B | ||
| Q3 24 | $20.7B | $-9.7B | ||
| Q2 24 | $20.4B | $-9.7B |
| Q1 26 | — | $68.9B | ||
| Q4 25 | $43.7B | $69.2B | ||
| Q3 25 | $42.7B | $67.1B | ||
| Q2 25 | $41.6B | $68.5B | ||
| Q1 25 | $40.1B | $65.1B | ||
| Q4 24 | $39.4B | $61.8B | ||
| Q3 24 | $38.1B | $66.9B | ||
| Q2 24 | $37.1B | $65.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.5B | 67% |
| Endoscopy | $736.0M | 14% |
| Urology | $646.0M | 12% |
| Neuromodulation | $318.0M | 6% |
PM
Segment breakdown not available.
